Oxford MEStar
Oxford MEStar develops and offers bioengineering products and services for translational and regenerative medicine. The company provides technologies and solutions to scale up human cell and stem cell processing, manufacture engineered tissues and cellular bioproducts, and apply bioprocessing and biomanufacturing expertise. It enables clients to access three-dimensional bioprinting, in vitro diagnostic development, and related bioengineering alternatives to advance tissue engineering and stem cell therapies.
1 past transactions
MODE Diagnostics
Acquisition in 2016
Mode Diagnostics is focused on developing innovative diagnostic products for bowel cancer screening. The company leverages the electrochemical properties of biomarkers to create novel assays suited for both physician offices and consumer self-testing. Its advanced suite of technologies includes assay development techniques, biosensing capabilities, microfabrication, electronics, and wireless communications. Mode's proprietary platform, measure, is designed to be flexible, low-cost, and hygienic, allowing for the easy configuration of health tests. The company's initial product, measure BOWEL HEALTH, significantly enhances existing methods for fecal occult blood testing, representing a notable advancement in bowel cancer screening. Through its user-friendly and medically informative health screening products, Mode Diagnostics aims to improve the efficiency of bowel cancer detection for healthcare providers and consumers alike.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.